Overview
EchoNext by Pathway Labs is an FDA-cleared artificial intelligence tool designed to analyze standard 12-lead electrocardiograms (ECGs) to identify signs of underlying structural heart disease that might otherwise go undetected. This innovative technology provides physicians with a non-invasive, accessible method for early screening and risk stratification.
The tool leverages advanced machine learning algorithms to interpret complex ECG patterns, looking for subtle indicators associated with conditions such as heart failure, various forms of valve disease, and pulmonary hypertension. By integrating EchoNext into routine clinical workflows, healthcare providers can enhance their diagnostic capabilities and potentially intervene earlier in the progression of these serious cardiac conditions.
EchoNext aims to improve patient outcomes by facilitating timely referrals and management strategies for individuals at risk. Its ability to extract critical insights from a commonly performed and inexpensive diagnostic test makes it a valuable asset for a wide range of clinical settings, from primary care to specialized cardiology practices.
Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Key Features
- AI-powered ECG analysis
- Detection of hidden structural heart disease
- Identifies heart failure risk
- Screens for valve disease
- Detects pulmonary hypertension indicators
- Utilizes standard 12-lead ECGs
- FDA-cleared technology
- Non-invasive diagnostic support
Use Cases
- Early screening for structural heart disease
- Risk stratification of patients with cardiac symptoms
- Enhancing diagnostic accuracy in primary care
- Supporting cardiology referrals
- Identifying patients for further cardiac evaluation
What Physicians Need to Know
EchoNext serves as a powerful front-line screening tool, particularly valuable in settings with limited access to echocardiography. It can help identify high-risk patients for structural heart disease who might otherwise be missed, enabling earlier intervention and potentially improving patient outcomes. While highly accurate in flagging risk, it is crucial to remember that EchoNext is a screening tool and not a standalone diagnostic. Positive findings should prompt further definitive imaging with echocardiography. The tool's ability to detect conditions 'the human eye can't' from an ECG can significantly enhance diagnostic pathways.
Pathway Labs is collaborating with OpenEvidence, a clinical decision platform used by over 500,000 U.S. physicians, to make EchoNext's screening tool widely available. This partnership aims to integrate AI-assisted ECG analysis into routine clinical workflows, expanding access to earlier heart disease screening across various care settings, from major hospitals to community practices.
Details
| Category | Cardiology AI, Clinical Decision Support & Reference, Lab & Diagnostics |
| Pricing |
Starts at $600/month
|
| Deployment | Available through the OpenEvidence clinical decision support platform. |
| Training | Unknown |
| Target Size | EchoNext is designed for broad access, from major hospitals to community practices. |
| Compliance | |
| BAA Available | Yes |
| HIPAA Compliant | Yes |
| FDA Status |
Yes EchoNext received FDA clearance on June 22, 2026, for six indications related to detecting high-risk structural heart diseases from standard 12-lead electrocardiograms (ECGs). These indications include right and left-sided heart failure, valve disease, severe hypertrophy compatible with infiltrative cardiomyopathy, and pulmonary hypertension. |
| Integrations | |
| EHR | Not specified |
| Specialties | Cardiology, Family Medicine, Hospital Medicine, Internal Medicine |
Social Proof
| Customers | unknown |
| Notable | EchoNext was developed by researchers at NewYork-Presbyterian and Columbia University Irving Medical Center. |
What the Web Says
EchoNext, developed by Pathway Labs, is an FDA-approved AI-powered electrocardiogram (ECG) model designed to detect hidden structural heart diseases (SHDs) that traditional ECGs often miss. It has demonstrated superior accuracy compared to cardiologists in identifying SHDs and aims to improve early detection, streamline patient care, and optimize the use of echocardiography resources.
Overall: PositiveStrengths
- Superior accuracy in detecting structural heart disease compared to cardiologists.
- Identifies a broad range of structural heart conditions, including valve disease, heart failure, and pulmonary hypertension.
- Utilizes standard, inexpensive ECGs, making screening more accessible and cost-effective.
- Reduces diagnostic delays and helps prioritize patients for timely echocardiography.
- Maintains consistent performance across diverse care settings and demographics.
- FDA approved for detecting six types of hidden heart disease.
Limitations
- Potential risks include patient anxiety from false positives or bias in clinical adoption, requiring further study.
- Cardiologists in comparative studies did not have access to full clinical context, which is not typical of standard clinical care.
- The prospective trial involved a relatively small number of patients (100) and used an earlier model for recruitment.
- External validation showed a slight drop in accuracy (AUROC of 78u201380%).
- The true disease status for most patients in real-world silent deployment was unknown.
- Questions remain about the impact of thousands of AI-flagged ECGs on emergency department workflows and cost-effectiveness.
Based on reviews from: Nature, NewYork-Presbyterian, Becker's Hospital Review, TechTarget, Healthline, Physics World, HLTH, ColumbiaDoctors, Capterra, Reddit, ResearchGate, YouTube, G2, Software Finder
Last updated: 2026-07-02
Ratings & Reviews
Rate EchoNext
Press & Coverage
Frequently Asked Questions
Compare EchoNext
VS
VS
VS
VS
